Global Prostate Cancer Market Size, Share, Analysis, Forecast, Industry Strategy, Opportunity, Trends, Insights, Growth, Price, Research Survey, Segment, Outlook and Challenges Report To 2023
Global Prostate Cancer Market Size, Share, Analysis, Forecast, Industry Strategy, Opportunity, Trends, Insights, Growth, Price, Research Survey, Segment, Outlook and Challenges Report To 2023
Increase in prevalence of Prostate cancer and availability of new treatment options( Zytiga, Xtandi, Cabazitaxel and Xofigo) in last few years has extended role of newer oral Antiandrogens to treat metastatic CRPC patient populations where the unmet need was high. This has expanded WW market size of Prostate cancer drugs to $ 7b in 2016 from $ 2.5b in 2011. Now nmCRPC, HSPC and Xtandi / Zytiga resistance population are the markets where in new pipeline drugs are under development.
Reported PhII clinical data of Xtandi, ARN-509 and ODM-201 in nmCRPC when indirectly compared demonstrate the bar is high for ARN-509 to compete against Xtandi in nmCRPC market and while ODM-201 is few years behind in clinical development. While in mHSPC reported clinical results of STAMPEDE study opens door for docetaxel combination approach as standard of care in first line setting.
Around 8 plus drugs are in PhIII development for Prostate cancer treatment and 26 plus drugs are in PhII development( 21 small molecules)- success of a few( ARN-509, ODM-201, AZD 5363, GX301) in coming years will expand nmCRPC($ 3.5be), mHSPC market($ 1be) and Xtandi / Zytiga resistant population($ 1be) market by 2023. Longer duration of therapy and high